172 related articles for article (PubMed ID: 37679999)
1. Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells.
Simiczyjew A; Wądzyńska J; Kot M; Ziętek M; Matkowski R; Hoang MP; Donizy P; Nowak D
J Cell Mol Med; 2023 Oct; 27(19):2995-3008. PubMed ID: 37679999
[TBL] [Abstract][Full Text] [Related]
2. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.
Dratkiewicz E; Pietraszek-Gremplewicz K; Simiczyjew A; Mazur AJ; Nowak D
Oncotarget; 2018 Apr; 9(26):18254-18268. PubMed ID: 29719603
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948
[TBL] [Abstract][Full Text] [Related]
5. Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines.
Simiczyjew A; Dratkiewicz E; Van Troys M; Ampe C; Styczeń I; Nowak D
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30227653
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Qu GP; Shi M; Wang D; Wu JH; Wang P; Gong ML; Zhang ZJ
BMC Pulm Med; 2021 Jul; 21(1):208. PubMed ID: 34210314
[TBL] [Abstract][Full Text] [Related]
7. EGF/EGFR Promotes Salivary Adenoid Cystic Carcinoma Cell Malignant Neural Invasion
Ren Y; Hong Y; He W; Liu Y; Chen W; Wen S; Sun M
Curr Cancer Drug Targets; 2022; 22(7):603-616. PubMed ID: 35410600
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
9. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
10. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
13. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
[TBL] [Abstract][Full Text] [Related]
14. The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways.
Candido S; Salemi R; Piccinin S; Falzone L; Libra M
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335966
[TBL] [Abstract][Full Text] [Related]
15. Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells' Invasive Abilities.
Simiczyjew A; Pietraszek-Gremplewicz K; Dratkiewicz E; Podgórska M; Matkowski R; Ziętek M; Nowak D
Front Pharmacol; 2019; 10():1116. PubMed ID: 31649529
[TBL] [Abstract][Full Text] [Related]
16. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
17. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.
Lee YY; Kim HP; Kang MJ; Cho BK; Han SW; Kim TY; Yi EC
Exp Mol Med; 2013 Nov; 45(11):e64. PubMed ID: 24263233
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
Meier F; Busch S; Lasithiotakis K; Kulms D; Garbe C; Maczey E; Herlyn M; Schittek B
Br J Dermatol; 2007 Jun; 156(6):1204-13. PubMed ID: 17388918
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P
Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
